statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Macquarie cuts Eris Life's target price amid earnings dilution from recent acquisitions

Macquarie expects Eris Life's domestic revenue to grow 12-14 percent with an EBITDA margin of around 36 percent.

Buy Eris Lifesciences; target of Rs 1100: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Eris Lifesciences has recommended buy rating on the stock with a target price of Rs 1100 in its research report dated May 22, 2024.

Stock Radar: BHEL, PI Industries, Metropolis, Sheela Foam, PNC Infratech, Biocon in focus on Wednesday

Grasim Industries, Sun Pharma, Power Grid Corporation, Paytm, Nykaa, Ashoka Buildcon, Dhanlaxmi Bank, GE Power India, Gland Pharma, GMM Pfaudler, HEG, Jubilant FoodWorks, New India Assurance Company, and Unichem Laboratories will announce their March quarter earnings on May 22.

Eris Lifesciences Q4 results: Net profit up 29.5% to Rs 79.6 crore

Eris Lifesciences Q4: Revenue came in at Rs 550.9 crore, up 36 percent from the year-ago quarter

Neutral Eris Lifesciences; target of Rs 930: Motilal Oswal

Motilal Oswal recommended Neutral rating on Eris Lifesciences with a target price of Rs 930 in its research report dated March 14, 2024.

Eris Lifesciences trades lower after buying branded formulation business of Biocon Biologics

Broking house Motilal Oswal maintained neutral on Eris Lifesciences with a price target of Rs 930.

Biocon Biologics  signs 10-year supply deal with Eris Lifesciences for Rs 1242 crore

As part of the deal over 430 employees associated with the business are expected to transition to Eris

Eris Lifesciences acquires 51% in Swiss Parenterals for Rs 637 crore

This deal also marks the entry of Eris into the RoW Export Markets.

Eris Lifesciences Ltd. engages in the provision of pharmaceutical products. Its brands include Eritel, Glimsave, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The firm markets and distributes pharmaceutical drugs, such as tablets, syrups and injections. The company was founded by Amit Indubhushan Bakshi on January 25, 2007 and is headquartered in Ahmedabad, India.

Volume	161,475.00
52-Wk High	1,098.65
52-Wk Low	767.10

ERIS.NSE Eris Lifesciences Ltd.

About

Feed

News

Sentiment

Fundamentals